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Early History 
If defined as the use of a specific compound discovered as the result of a systematic search for a 
cure for a specific disease, then chemotherapy is less than a century old.  The first example was 
the introduction in 1910 by Paul Ehrlich1,2 of an organoarsenic compound he named Salvarsan,
which provided the first real cure for the extremely unpleasant disease syphilis (caused by the 
parasitic spirochete Treponema pallidum).  As is well-known, the compound was also called 
Ehrlich 606 because it was the 606th compound tested by Ehrlich in conjunction with his 
colleagues Bertheim (synthesis) and Hata (biological testing) (Figs. 1 & 2).3,4 
Salvarsan’s origins can be traced to 1863, when Pierre Bechamp (famous for his discovery of the 
Bechamp process for the cheap production of aniline) isolated a compound from a reaction 
between arsenic acid and aniline.  He characterised this compound as 1, the anilide of arsenic 
acid.  It was shown later that Bechamp’s compound was less toxic that inorganic arsenic 
compounds and so it was given the informal name of Atoxyl.3,4 In 1905, Thomas published a 
paper5 which showed that Bechamp’s compound was effective in the treatment of sleeping 
sickness, the greatest cause of death in Africa at the time.  This paper caught the attention of Paul 
Ehrlich.   
 
Ehrlich was born in 1854 in what is now Strzelin, Poland.  He started his scientific career as a 
medical student, and became interested in the new dyes which were becoming available at the 
time.  He started working in the field of immunology, convinced that the body’s immune system 
could be fortified by chemical means. His interest in dyes – specifically their ability to 
selectively stain microbes – is what sparked his interest in chemotherapy.  In simple terms, the 
idea was that if a dye could selectively target a micro-organism, and the functional groups 
responsible could be included in a molecule that was also toxic to the micro-organism then you 
would have a specific chemotherapeutic agent.6
When Alfred Bertheim arrived in Ehrlich’s laboratory he worked on Bechamp’s Atoxyl 1, which 
was still thought to be an anilide of arsenic acid.  It was quickly realised that the structure was 
incorrect and structure 2 was adopted, but not without controversy.3 Ehrlich’s lab then embarked 
on a systematic study of different compounds, starting from Atoxyl in order to find compounds 
with improved activity specifically against syphilis.  The best candidate was Salvarsan for which 
Ehrlich assigned structure 3 (Fig. 3).1
The introduction of Salvarsan was a major event, and the compound rapidly became the most 
widely prescribed drug in the world (necessitating emergency synthesis programmes in England, 
the US, and Japan after 1914 when the supply of German Salvarsan from the Hoechst plant was 
interrupted by the war).  By 1920 Salvarsan had been shown to be effective against other parasitic 
disease6 and 2 million doses a year were produced in the US alone.7 Demand for Salvarsan 
remained very strong until 1943 when penicillin became available – an equally effective and 
more pleasant remedy.   
 
Preparation of Salavarsan 
Despite its wide use, Salavarsan has remained an enigmatic material.  Ehrlich’s synthesis 
involved the reduction of the substituted phenylarsonic acid with dithionite (Eq. 1)1 in a reaction 
that was not straightforward; the products had variable toxicity such that up to 50% of batches 
from Ehrlich’s operation were reported to be rejected.8 This has been attributed to the presence 
of unidentified sulfur-containing impurities that were derived from the dithionite.9 An 
alternative, two-step synthesis was more reliable (Eq. 2).10 
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Prepared in this way, Salvarsan is a pale-yellow powder.  The neutral form is very easily oxidized 
so it was isolated as the HCl salt, which can be handled for short periods in air without 
deterioration.  Administration of the drug by the physician was not straightforward – the typical 
average dose of 0.4 g of the salt was dissolved in water, neutralized by adding the exact 
calculated amount of aqueous NaOH, filtered to remove any undissolved material, and then made 
up to ca. 300 mL with saline solution.  This solution was warmed to physiological temperature 
and injected.  Ans all this with minimum exposure to air to avoid oxidation! Needless to say, 
there were many cases of medical misadventure, when the process was not followed exactly.   
 
What is Salvarsan? 
It is intriguing that despite its long history, and commercial and medical importance, the chemical 
constitution of Salvarsan is still undecided (try introducing a new pharmaceutical today without 
knowing exactly what it consists of!).  The empirical formula of the material was well-established 
by Ehrlich’s team as the arsenic(I) species, RAs.HCl.H2O (R = 3-amino-4-hydroxyphenyl).  
While this is not in question, Ehrlich had assigned the structure 3, with an As=As double bond, to 
the base (Fig. 3).  This seemed reasonable at the time, since corresponding congeneric azo 
compounds RN=NR were well established.  However, as inorganic chemistry developed it 
became apparent that this formulation was untenable11 since As=As double bonds (unlike those 
of nitrogen) are only stable in exotic molecules with extensive steric protection.12 Various 
attempts at measuring physical properties have been made over the years, but full chemical 
characterization has been elusive.  Textbooks and reviews still quote 3, the original incorrect 
Ehrlich structure;13 various other suggestions for polymeric or oligomeric structures have been 
proposed but with little supporting evidence.14 The reasons why Salvarsan has proved so 
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intransigent include: i) it is actually a mixture of species, ii) it can only be isolated as an 
amorphous powder that precludes X-ray crystallography, iii) as a free base it is oxidized very 
readily to As(III), iv) in aqueous solution it is reactive and appears to undergo strong 
intermolecular hydrogen-bonding interactions that give gels at particular concentrations/pH 
values, and v) it is non-volatile so traditional mass spectrometry does not provide useful 
information.  It is, therefore, a particularly difficult compound to deal with.   
 
Why the current interest? 
Given its widespread use as a cure for syphilis, surprisingly little is known about the mode of 
action.  Discovering this and site of action for a compound of uncertain composition is not easy.  
Since it is effective against a range of obligate pathogens, it must presumably affect a target 
present in the pathogen but absent (or reduced) in the human host.  Advances in molecular 
biology and in our understanding of the structure of the active components of Salvarsan create 
new opportunities to detect the target and understand the mode of action.  In 1997 the complete 
genome of the syphilis organism was sequenced15 so that, in theory, every protein the pathogen 
synthesises can be identified and by molecular techniques it can be cloned and expressed in large 
quantities in a suitable benign host, e.g. E. coli. Doing this for every protein would be an 
enormous task but two approaches can make it simpler.  Firstly, one can mine the sequence 
database to look for key enzymes in the genome of the pathogen that have a different structure 
from equivalent enzymes in the human genome – these become prime targets for selective 
toxicity.  Secondly, because we can now produce large quantities of the active component of 
Salavarsan in pure form, one can manufacture affinity columns with the active component 
attached.  By passing protein extracts from the pathogen through this column those that interact 
will be separated from proteins which have no affinity.  The former proteins can then be eluted, 
their amino acid sequence determined, and the corresponding gene (and possibly enzyme 
activity) identified from the genome sequence.  Finally, tests of inhibition of these enzymes by 
Salavarsan can be conducted following cloning and expression.  Therefore, we decided to 
reinvestigate the chemistry of Salvarsan and related species to establish their true chemical 
identity and to see if the target enzymes and mode of action could be established.   
 
Waikato studies 
The initial goal was to establish a reliable synthesis of Salvarsan.  This was no trivial exercise but 
conditions have been established whereby both the direct Ehrlich method and the modified one 
(Eq. 1 & 2) give a consistent material that analyzes correctly for RAs.HCl.H2O.  In studies 
detailed elsewhere,16 we used electrospray mass spectrometry to examine our material.  This 
relatively new technique has the ability to analyse species directly from solution without the need 
for intrinsic volatility, and the chemical ionization involved occurs under very mild conditions so 
that ions are transferred generally without fragmentation.  This makes interpretation relatively 
straightforward, even for mixtures, since each peak can be related to a single parent molecule or 
ion.17 For Salvarsan this showed the compound to be a complex mixture with the main 
constituents as small ring cyclopolyarsines [RAs]n (n = 3-6), e.g. 4 and 5, together with small 
amounts of larger rings.  Variable amounts of partially oxidized materials [RAs]nO1-2, some 
sulfur-containing impurities [RAs]nS as well as the fully oxidized arsenic(III) compound 
RAs(OH)2, 6, wee also present.  Compound 6 is particularly important since it is generally 
assumed to be the active form, generated by in situ oxidation of Salvarsan, though this has still to 
be fully proved.   
 
To provide a link to Ehrlich we were fortunate to be supplied with some original Salvarsan from 
the archives of the Georg Speyer Haus (the Frankfurt research institute established for Ehrlich by 
Frau Speyer) (Fig. 3).  This was examined by electrospray mass spectrometry under the same 
conditions used for our own material; the resulting patterns were closely similar, showing that 
our syntheses had reproduced the original ones, and that Ehrlich’s Salvarsan had survived 
essentially unchanged for 80 years or so.   
 
With a reliable source of Salvarsan we can turn our attention to further characterization of it and 
its close variants, and carry out tests to see if its mode of biological activity can be determined. 
Despite interest in this area having a strong historical component, the information obtained may 
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lead to new disease treatments as organoarsenic drugs are still used for treating some Third 
World parasitic diseases,18 and are reported to even cure Chronic Fatigue Syndrome in falcons 
and parrots!19 With developing resistance to antibiotics, Salvarsan itself may even one day return 
as a treatment for syphilis. 
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Figure 1.  Ehrlich and Hata. 
Figure 2.  Ehrlich’s death mask exhibited on the 150th 
anniversary of his birth at the World Conference on Dosing 
with Anti-infectives, Nurnberg, Sept. 2004.   
 
Figure 3.  Entry in Ehrlich’s book assigning 2 to “606”;7 Sept. 1909.   
Figure 4.  Ampoules containing Salvarsan and Neosalvarsan from Ehrlich’s laboratory.   
 
